List of Excipients in Branded Drug CETIRIZINE HYDROCHLORIDE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing CETIRIZINE HYDROCHLORIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Torrent Pharma Inc	cetirizine hydrochloride oral solution	13668-029	ACETIC ACID
Torrent Pharma Inc	cetirizine hydrochloride oral solution	13668-029	GLYCERIN
Torrent Pharma Inc	cetirizine hydrochloride oral solution	13668-029	GRAPE
Torrent Pharma Inc	cetirizine hydrochloride oral solution	13668-029	METHYLPARABEN
Torrent Pharma Inc	cetirizine hydrochloride oral solution	13668-029	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in CETIRIZINE HYDROCHLORIDE ORAL SOLUTION?

# Of NDCs	Excipient
4	ACETIC ACID
1	CALCIUM ACETATE
4	GLYCERIN
3	GRAPE
4	METHYLPARABEN

Cetirizine Hydrochloride Oral Solution: Excipient Strategy, Regulatory Position, and Commercial Opportunities

Last updated: September 5, 2026

Cetirizine hydrochloride oral solution is a mature, low-cost antihistamine product with limited active-ingredient exclusivity and substantial formulation competition. Commercial differentiation depends on excipient selection, taste, preservative profile, dosing accuracy, packaging, and channel positioning rather than new chemical-entity patents. The strongest opportunities are pediatric palatability, sugar-free and dye-free formulations, alcohol-free products, preservative reduction, and improved multidose packaging.

What is the market and regulatory position of cetirizine hydrochloride oral solution?

Cetirizine hydrochloride is the hydrochloride salt of cetirizine, a second-generation H1 antihistamine used for allergic rhinitis and chronic urticaria. Oral solutions generally contain 1 mg/mL of cetirizine hydrochloride, equivalent to 1 mg/mL cetirizine on a molar basis.

In the United States, cetirizine is available through prescription products, OTC products, generic equivalents, and private-label retail products. The original Zyrtec product was developed by UCB and commercialized in the United States by Pfizer. Cetirizine later moved into the OTC market, where it competes with loratadine, fexofenadine, diphenhydramine, and branded and store-brand combination products.

The commercial product categories include:

Product category	Typical concentration	Primary channel	Commercial position
Cetirizine oral solution	1 mg/mL	Retail, pediatric, OTC	High-volume generic and private-label category
Cetirizine oral syrup or solution equivalent	Usually 1 mg/mL	Retail and institutional	Differentiated by flavor, sugar content, and packaging
Cetirizine tablets	5 mg or 10 mg	Retail and prescription	Lower excipient complexity
Cetirizine chewable tablets	5 mg or 10 mg	Pediatric and OTC	Competes directly with liquid products
Cetirizine combination products	Variable	OTC	Adds congestion or cough positioning

FDA labeling commonly identifies cetirizine oral solution as an oral liquid containing cetirizine hydrochloride equivalent to 1 mg/mL cetirizine. Product-specific inactive ingredients differ by manufacturer and may include sweeteners, polyols, buffers, preservatives, flavoring agents, viscosity modifiers, and pH adjusters.[1-3]

When does cetirizine lose exclusivity?

Cetirizine has no meaningful remaining compound-patent exclusivity in the United States. The original cetirizine patent estate expired many years ago, and the product is now exposed to generic, OTC, and private-label competition.

Patent and exclusivity timeline

Milestone	Approximate status
Original cetirizine compound patents	Expired
U.S. prescription-market exclusivity	Expired
OTC switch	Completed
Generic oral solution availability	Established
Active ingredient exclusivity	None expected
Biosimilar exclusivity	Not applicable
Current competitive barrier	Formulation execution, supply, quality, branding, and distribution

Cetirizine is a small-molecule drug. Biosimilar regulation does not apply. Competitive entry generally proceeds through an abbreviated new drug application, an OTC monograph pathway where applicable, or an NDA or supplemental NDA depending on the product’s regulatory basis.

What patents protect cetirizine hydrochloride oral solution?

No broad, commercially meaningful patent protection remains for the cetirizine active ingredient. Any current patent value is more likely to arise from a specific formulation, delivery device, manufacturing process, flavor system, packaging configuration, or combination product.

Compound patents

The original cetirizine patent family covered the active compound and related antihistamine chemistry. Those rights have expired in the United States and major European markets. A new entrant should not treat cetirizine hydrochloride itself as a defensible patent position.

Formulation patents

A formulation patent could cover:

• A defined pH range combined with a particular preservative system.
• A specific flavor-masking composition.
• A low-sugar or sugar-free oral solution.
• A preservative-free unit-dose package.
• A high-concentration product designed to reduce administration volume.
• A viscosity-controlled formulation that limits sedimentation or dosing variability.
• A polymer, cyclodextrin, or complexing agent used to improve taste or stability.
• A dosing device integrated with the bottle or closure.
• A child-resistant package combined with a specific delivery mechanism.

A formulation claim must provide a meaningful technical distinction. Broad claims covering cetirizine, water, sweetener, flavor, and preservative are vulnerable to written-description, enablement, obviousness, and anticipation challenges. Commercial value is stronger where the formulation solves a measurable problem such as bitterness, chemical instability, microbial control, dose-volume reduction, or delivery accuracy.

Method-of-use patents

Method-of-use patents have limited value for standard cetirizine oral solution because the principal indications are well established. Potential claims could address:

• A specific dosing regimen for a defined pediatric population.
• Use in a narrow patient subgroup.
• A combination regimen with another active ingredient.
• A defined treatment sequence or dosing schedule.

Such patents would face substantial invalidity and infringement risks if the claimed use overlaps established antihistamine labeling or routine clinical practice.

What excipients are used in cetirizine hydrochloride oral solution?

Common excipient classes include:

Excipient class	Typical function	Strategic considerations
Purified water	Vehicle	Must meet pharmaceutical water specifications
Glycerin	Co-solvent, sweetener, mouthfeel modifier	Supports body and palatability; can increase viscosity
Propylene glycol	Co-solvent and flavor carrier	Useful for flavor systems; requires pediatric and labeling review
Sorbitol	Sweetener and bulking agent	Sugar-free positioning; excessive levels may cause gastrointestinal effects
Sucrose	Sweetener and viscosity contributor	Familiar taste but weakens sugar-free positioning
Sucralose or saccharin sodium	High-intensity sweetener	Enables low-sugar formulations; taste profile must be balanced
Sodium citrate or sodium acetate	Buffer	Controls pH and may affect taste and preservative performance
Citric or acetic acid	pH adjustment and acidulant	Can improve flavor balance but may increase sourness
Sodium benzoate or other preservatives	Microbial protection	Supports multidose packaging; regulatory and tolerance considerations apply
Methylparaben or propylparaben	Preservative	Effective at low concentration but may limit consumer positioning
Flavoring agents	Taste masking	Major commercial differentiator
Coloring agents	Appearance	Adds regulatory and consumer sensitivity issues
Chelating agents	Metal-ion control	May improve oxidative stability in selected systems
Viscosity modifiers	Flow and mouthfeel control	Can improve dosing consistency but complicate filling and cleaning

Actual excipient composition varies among approved products. FDA labeling and DailyMed records should control any product-specific assessment.[1-3]

Which excipients create the strongest commercial opportunities?

The highest-value excipient strategy is not the addition of more ingredients. It is the removal or optimization of ingredients that create safety, tolerability, consumer, or manufacturing objections.

Sugar-free and low-sugar formulations

Sugar-free cetirizine oral solution is commercially attractive for:

• Children with repeated seasonal dosing.
• Consumers monitoring sugar intake.
• Dental-health-conscious households.
• Institutional and hospital formularies.
• Private-label retailers seeking differentiated claims.

Sorbitol, glycerin, sucralose, and saccharin sodium can support sugar-free positioning. The formulation must control aftertaste, cooling sensation, and gastrointestinal tolerance. High polyol loading can cause loose stools or abdominal discomfort, especially when administered repeatedly or at larger volumes.

A low-sugar product may offer a better sensory profile than a fully sugar-free formulation but creates more complicated marketing and labeling decisions. The commercial choice should be based on taste testing rather than excipient convention.

Pediatric taste masking

Taste is a core determinant of repeat use and caregiver acceptance. Cetirizine is generally easier to formulate than strongly bitter drugs, but the salt form, buffer, preservatives, and flavor system can produce bitterness, sourness, or medicinal aftertaste.

Effective taste-masking programs should assess:

1. Immediate bitterness.
2. Delayed bitterness after swallowing.
3. Sweetness intensity.
4. Flavor persistence.
5. Mouth coating.
6. Acceptance after repeated dosing.
7. Compatibility with the active ingredient and preservative system.

Fruit flavors such as grape, berry, cherry, and mixed fruit are common in pediatric liquids. A single flavor may not optimize acceptance across age groups. A fruit-forward system with controlled acidity and a secondary masking flavor can outperform a high-sweetener approach.

Cyclodextrins, ion-exchange resins, polymeric taste blockers, and lipid-based systems could provide patentable technical differentiation. Their value depends on whether they reduce bitterness without impairing release, increasing sedimentation, complicating manufacturing, or creating a new regulatory burden.

Preservative-free and reduced-preservative products

Multidose aqueous oral solutions require microbial-control strategies. Preservatives can be reduced or removed only if the packaging, formulation, manufacturing process, and in-use stability program support the claim.

Potential approaches include:

• Unit-dose ampoules or sachets.
• Single-use oral syringes.
• Blow-fill-seal packaging.
• Aseptic filling.
• Low-water-activity formulations.
• pH optimization.
• Closure systems that limit microbial ingress.
• Smaller package sizes designed for short in-use periods.

Preservative-free packaging can command a price premium in pediatric, hospital, and specialty retail channels. The tradeoff is higher packaging cost, lower shipping efficiency, and more complex production validation.

Dye-free formulations

Dye-free products are commercially relevant because parents and institutional buyers increasingly prefer simpler excipient profiles. Removing colorants reduces the risk of consumer objections and simplifies certain product claims. Appearance must remain consistent across the product shelf life, particularly if the formulation is naturally colored by flavor components or undergoes pH-related changes.

How should the pH and preservative system be designed?

The formulation should balance chemical stability, taste, preservative efficacy, and packaging compatibility. A lower pH may improve preservative performance but can create sourness, enamel concerns, or discomfort. A higher pH may improve taste but reduce the proportion of unionized preservative and weaken microbial protection.

A development program should establish:

Parameter	Commercial objective
pH	Stability and preservative efficacy without excessive sourness
Osmolality	Pediatric tolerability and acceptable mouthfeel
Viscosity	Accurate dosing without slow pouring or syringe retention
Preservative concentration	Microbial protection with acceptable tolerability
Water activity	Support for microbial control where relevant
Container compatibility	No sorption, leaching, discoloration, or closure failure
In-use stability	Reliable performance after opening
Flavor stability	Consistent sensory profile through expiry
Dose uniformity	Accurate delivery at the beginning and end of the bottle

Preservative efficacy testing should be conducted using the final commercial package. The bottle, closure, dosing syringe, headspace, and expected consumer handling can materially affect microbial performance.

What FDA regulatory pathway applies to cetirizine oral solution?

The appropriate pathway depends on the product’s legal status and intended labeling.

Prescription and generic pathway

A prescription generic product generally requires an ANDA demonstrating pharmaceutical equivalence and bioequivalence or another FDA-accepted basis for approval. For an oral solution, bioequivalence may be addressed differently from a solid oral dosage form because the active ingredient is already dissolved. The applicant must still establish pharmaceutical quality, sameness or acceptable differences in inactive ingredients, manufacturing controls, and labeling.

Excipient differences can trigger additional review if they affect:

• Pediatric safety.
• Local tolerability.
• Absorption.
• Stability.
• Microbial quality.
• Inactive-ingredient precedent.
• Flavoring or coloring exposure.

OTC pathway

OTC cetirizine products may use the applicable OTC monograph framework or an approved NDA, depending on the product and market history. The sponsor must align active ingredient, dosage, warnings, indications, labeling, and permitted dosage forms with the relevant FDA requirements.[4]

OTC launch execution requires attention to:

• Drug Facts labeling.
• Child-resistant packaging where applicable.
• Measuring-device instructions.
• Age-based dosing.
• Allergy and sedation warnings.
• Manufacturing site registration and listing.
• Complaint and adverse-event systems.
• Retailer-specific packaging and barcoding.

What is the Orange Book status of cetirizine oral solution?

The Orange Book is most relevant to approved NDA and ANDA products. It is less central to OTC-monograph products that are marketed without relying on a listed NDA.

For an individual cetirizine oral solution, Orange Book review should identify:

• The reference listed drug.
• Approved dosage form and strength.
• Therapeutic-equivalence codes.
• Listed patents, if any.
• Pediatric exclusivity, if any.
• Whether the product is approved under an NDA or ANDA.

No meaningful active ingredient patent barrier is expected for standard cetirizine hydrochloride oral solution. A current applicant should verify product-specific listings before filing because Orange Book status can differ by sponsor, dosage form, and regulatory history.[5]

Are Paragraph IV challenges relevant to cetirizine oral solution?

Paragraph IV litigation risk is low for the standard product because the key compound and market-entry barriers have expired. A Paragraph IV certification could still arise if an applicant encounters a listed formulation, method-of-use, or device patent. Such a patent would need to be materially relevant to the proposed product.

Potential disputes could concern:

• A listed formulation patent.
• A flavor-masking technology.
• A combination product.
• A dosing device.
• An extended-release or modified-delivery system.
• A patented packaging configuration.

For a conventional 1 mg/mL oral solution using standard excipients, the more likely risks are regulatory deficiencies, formulation failure, supply disruption, and retailer competition rather than patent litigation.

Which companies are challenging or competing with cetirizine products?

The category is heavily populated by generic and private-label manufacturers. Competition generally includes:

• Large generic manufacturers with national distribution.
• OTC brand owners.
• Retailer-owned private labels.
• Contract development and manufacturing organizations.
• Regional pediatric and hospital suppliers.

The main competing active ingredients are:

Active ingredient	Competitive distinction
Cetirizine	Strong efficacy, once-daily positioning, established pediatric use
Loratadine	Once-daily, generally marketed as less sedating
Fexofenadine	Non-sedating positioning and liquid pediatric products
Diphenhydramine	Older product with stronger sedation concerns
Levocetirizine	Related active ingredient with premium or prescription positioning

Product-level competitor analysis should compare retail price, bottle size, concentration, flavor, dosing device, age indication, preservative profile, and retailer placement.

How strong is the patent estate for cetirizine hydrochloride oral solution?

The patent estate is weak for the active ingredient and potentially moderate for a genuinely differentiated formulation.

Asset type	Current strength
Cetirizine compound patent	None in ordinary commercial markets
Standard 1 mg/mL solution	Low patent defensibility
Taste-masked solution	Moderate if supported by comparative data
Preservative-free unit dose	Moderate if packaging and process claims are narrow and functional
High-concentration solution	Moderate if stability and dosing benefits are demonstrated
Integrated dosing device	Moderate, subject to design-around risk
Manufacturing process	Low to moderate unless difficult to reproduce
Branding and trade dress	Potentially meaningful in OTC retail
Regulatory exclusivity	Generally absent for mature cetirizine products

A strong patent filing would include composition, process, package, and use claims supported by stability, microbial, sensory, and dose-delivery data. A single broad composition patent would be easier to design around.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are manageable but not trivial. The main technical risks are:

• Incomplete dissolution or local concentration gradients.
• pH drift during storage.
• Preservative loss or reduced efficacy.
• Flavor degradation.
• Interaction with plastic bottles or closures.
• Active adsorption to dosing devices.
• Microbial contamination after opening.
• Inaccurate dose delivery due to viscosity or foaming.
• Variation in raw-material flavor and sweetener quality.

A robust manufacturing process should control addition order, mixing energy, temperature, pH adjustment, deaeration, bulk hold time, filtration where appropriate, and filling conditions.

The most defensible manufacturing IP may relate to a specific sequence or control strategy that improves stability or preservative performance. Process patents have limited commercial force if competitors can achieve equivalent product quality through a different sequence.

What generic launch scenarios exist?

Scenario 1: Low-cost standard generic

A conventional 1 mg/mL product using familiar excipients competes on price, availability, and retailer access. Patent risk is low, but margins are vulnerable to purchasing concentration and supply tenders.

Scenario 2: Premium pediatric formulation

A sugar-free, dye-free, alcohol-free product with improved flavor and a calibrated oral syringe can support a retail premium. Evidence of superior taste acceptance and dosing accuracy is important.

Scenario 3: Preservative-free unit dose

Unit-dose packaging targets hospitals, pediatric clinics, travel use, and consumers seeking simplified excipient profiles. Packaging cost and manufacturing complexity are higher.

Scenario 4: High-concentration liquid

A more concentrated product could reduce administration volume, but it requires careful pediatric safety review, labeling controls, dosing-device design, and differentiation from existing 1 mg/mL products.

Scenario 5: Private-label platform

A manufacturer can use one validated liquid platform with retailer-specific flavor, bottle size, label, and dosing device. This approach improves manufacturing efficiency but increases change-control and supply-chain complexity.

What commercial metrics determine success?

For a mature antihistamine liquid, the central commercial metrics are:

• Cost of goods per bottle.
• Fill-weight yield.
• Active and excipient loss during manufacture.
• Stability failure rate.
• Preservative efficacy performance.
• Complaint rate related to taste or dosing.
• Repeat purchase rate.
• Retailer gross margin.
• Stock-out frequency.
• Bottle and closure cost.
• Syringe or dosing-cup cost.
• Freight cost per dose.
• Price premium for sugar-free or preservative-free positioning.

Revenue exposure is determined by channel access rather than patent duration. A low-cost standard product may generate volume but limited margin. A differentiated formulation can improve margin but carries higher development, packaging, and quality-control costs.

Key Takeaways

• Cetirizine hydrochloride oral solution is a mature, largely off-patent market.
• Standard 1 mg/mL products have low patent defensibility and high generic competition.
• Excipient strategy is the primary route to commercial differentiation.
• The strongest opportunities are sugar-free, dye-free, alcohol-free, pediatric taste-masked, preservative-reduced, and unit-dose products.
• Flavor, mouthfeel, in-use stability, preservative performance, and dosing accuracy should be developed as an integrated system.
• A formulation patent requires comparative technical data, not a routine list of excipients.
• OTC and generic pathways are established, but product-specific FDA and Orange Book status must be verified for the intended regulatory route.
• Biosimilar risk is irrelevant because cetirizine is a small-molecule drug.
• Standard products face limited Paragraph IV risk; formulation and device patents could create narrower disputes.
• Commercial success depends more on retail distribution, supply reliability, product experience, and packaging economics than on active-ingredient exclusivity.

FAQs

Can cetirizine oral solution be formulated without preservatives?

Yes. A preservative-free product generally requires unit-dose packaging, aseptic processing, or another validated microbial-control strategy. A conventional multidose bottle without preservatives carries higher contamination risk.

Is propylene glycol necessary in cetirizine oral solution?

No. Propylene glycol is commonly used as a co-solvent or flavor carrier, but alternative systems may use glycerin, ethanol where legally and commercially acceptable, surfactants, cyclodextrins, or a different flavor-solubilization approach.

What is the best sweetener system for pediatric cetirizine liquid?

There is no universal optimum. Sucrose often provides strong taste performance, while sorbitol, glycerin, sucralose, and saccharin sodium support sugar-free or reduced-sugar positioning. The final choice should be based on repeated-use sensory testing and gastrointestinal tolerability.

Can a cetirizine oral solution use a dosing syringe instead of a cup?

Yes. An oral syringe generally improves dose accuracy, particularly for pediatric administration. The syringe must be compatible with the formulation and validated for dose delivery across the bottle’s shelf life and in-use period.

Can a new flavor of cetirizine oral solution receive patent protection?

A flavor alone is rarely a strong patent asset. Protection is more credible when the flavor is part of a defined composition that produces demonstrated improvements in bitterness, stability, preservative performance, or patient acceptance.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Cetirizine hydrochloride oral solution prescribing information. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). DailyMed: Zyrtec cetirizine hydrochloride oral solution labeling. National Library of Medicine.

3. National Library of Medicine. (n.d.). DailyMed drug label database. https://dailymed.nlm.nih.gov/

4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Antihistamine drug products for over-the-counter human use. https://www.fda.gov/

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm

6. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

7. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. U.S. Department of Health and Human Services.